PERSPECTA

News from every angle

← Back to headlines

Teva Backs $125 Million Bid for BioXcel Assets Amid Bankruptcy-Sale Debate

The pharmaceutical company supports a cash-plus-liabilities acquisition deal, raising questions about whether the opportunity outweighs potential bankruptcy risks.

4 Sept, 16:01 — 4 Sept, 16:01
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual1d ago

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Read full article →

Related Stories

OPEC+ Maintains Oil Output Policy Unchanged for October

1h ago

China Injects Billions into State Banks and Insurers

1h ago

Reports: Iran Planning Multi-Front Attack on Israel via Proxies

2h ago

Jaguar Land Rover Announces Up to 4,000 Job Cuts Amid Pressure

2h ago